^
    1m
    Safety and Efficacy Study of CI-135 CAR-T Cells in Subjects with Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=0, Withdrawn, Beijing Boren Hospital | Trial completion date: Dec 2025 --> Dec 2023 | Recruiting --> Withdrawn | Trial primary completion date: Dec 2024 --> Dec 2023
    Trial completion date • Trial withdrawal • Trial primary completion date • CAR T-Cell Therapy
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    FLT3 mutation • FLT3 expression
    |
    cyclophosphamide • CI-135 CAR-T
    almost2years
    Safety and Efficacy Study of CI-135 CAR-T Cells in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=7, Recruiting, Beijing Boren Hospital | Trial completion date: Dec 2023 --> Dec 2025 | Trial primary completion date: Dec 2022 --> Dec 2024
    Trial completion date • Trial primary completion date • CAR T-Cell Therapy
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    FLT3 mutation • FLT3 expression
    |
    cyclophosphamide • CI-135 CAR-T